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ABSTRACT
Objective Randomised controlled trials, a gold-
standard approach to reduce uncertainties in clinical
practice, are growing in cost and are often slow to
recruit. We determined whether methodological
approaches to facilitate large, efﬁcient clinical trials were
acceptable to UK research ethics committees (RECs).
Design We developed a protocol in collaboration with
parents, for a comparative-effectiveness, randomised
controlled trial comparing two widely used blood
transfusion practices in preterm infants. We incorporated
four approaches to improve recruitment and efﬁciency: (i)
point-of-care design using electronic patient records for
patient identiﬁcation, randomisation and data
acquisition, (ii) short two-page information sheet; (iii)
explicit mention of possible inclusion beneﬁt; (iv) opt-out
consent with enrolment as the default. With the support
of the UK Health Research Authority, we submitted an
identical protocol to 12 UK REC.
Setting RECs in the UK.
Main outcome Number of REC granting favourable
opinions.
Results The use of electronic patient records was
acceptable to all RECs; one REC raised concerns about
the short parent information sheet, 10 about inclusion
beneﬁt and 9 about opt-out consent. Following
responses to queries, nine RECs granted a favourable
ﬁnal opinion and three rejected the application because
they considered the opt-out consent process invalid.
Conclusions A majority of RECs in this study consider
the use of electronic patient record data, short
information sheets, opt-out consent and mention of
possible inclusion beneﬁt to be acceptable in neonatal
comparative-effectiveness research. We identiﬁed a need
for guidance for RECs in relation to opt-out consent
processes. These methods provide opportunity to
facilitate large randomised controlled trials.
INTRODUCTION
The advancement of patient care requires incre-
mental reductions in the uncertainties found in
routine practice, in addition to the development of
new therapies. Rigorous randomised controlled
trials are recognised as the gold-standard methodo-
logical approach to achieve these aims, but com-
monly require large sample sizes to detect clinically
relevant effects. Concerns have been expressed
about the rising ﬁnancial burden and regulatory
complexities of conventional randomised con-
trolled trials. It has also been estimated that up to
85% of research investment is wasted,1 with exam-
ples including inefﬁcient delivery and unduly
restrictive regulation.2
Large trials require effective recruitment and efﬁ-
cient data acquisition.3 Methods to increase
recruitment include informing participants of the
potential beneﬁts of enrolling in a clinical trial,4
consent processes that involve opportunity to opt
out with enrolment as the default5 and short,
simple participant information sheets.6 7 The efﬁ-
ciency of data acquisition can be improved by using
electronic patient records (EPRs) in what are
referred to as ‘point-of-care trials’.8 However,
despite evidence for the effectiveness of these
approaches,9 10 take-up has been limited and the
extent to which regulatory barriers are contributory
is unclear.
A key component of regulation is to ensure
studies conform to agreed principles of research
ethics. In many countries such as the UK, this is the
responsibility of independent research ethics com-
mittees (RECs). The UK RECs were established in
1991 to review research conducted within the
National Health Service (NHS). For multisite
research, approval is sought from a single REC.
The UK Health Research Authority (HRA) that has
responsibility for RECs was established in 2011 to
What is already known on this topic?
▸ High-quality randomised controlled trials are
the gold-standard way to reduce uncertainties
in clinical care, but are increasingly expensive
and burdensome.
▸ Evidence-based methods to make randomised
controlled trials more efﬁcient exist, but are
seldom used in the UK.
▸ It is not known the degree to which regulation,
such Research Ethics Committees review,
contributes to inefﬁciency in randomised
clinical trials.
What this study adds?
▸ The UK Research Ethics Committees ﬁnd the
use of electronic patient records, short
participant information sheets and mention of
inclusion beneﬁt to be acceptable in neonatal
comparative effectiveness research.
▸ There is inconsistency between the UK Research
Ethics Committees in relation to the validity of
opt-out consent processes for neonatal
comparative effectiveness research.
▸ The wider application of these methods may
facilitate larger, more efﬁcient randomised
controlled trials.
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promote and protect the interests of patients in health research
and streamline regulation.
We aimed to determine the acceptability to the UK RECs of
methods to facilitate efﬁcient, large, simple clinical trials. We
tested the hypotheses that methods would be acceptable and
decision-making consistent.
METHODS
The WithHolding Enteral feeds Around packed red cell
Transfusion (WHEAT) trial is a multicentre, comparative effect-
iveness, point-of-care trial. We designed the WHEAT trial to
address a clinical uncertainty identiﬁed as important by service
users and clinicians in the ﬁeld of preterm birth.11 The aim of
the WHEAT trial is to compare two practices that are both in
wide current clinical use (withholding enteral feeding or con-
tinuing normal feeding) during blood transfusion in preterm
babies with the hope of reducing the incidence of necrotising
enterocolitis (see box 1). WHEAT is a real trial being developed
by an investigator group with the support of the UK neonatal
clinical care community, has incorporated parent involvement
from inception and is supported by a National Institute of
Health Research Enabling Involvement grant.12
The WHEAT trial includes the following approaches to facilitate
efﬁcient data collection and recruitment:
1. A point-of-care trial design where all trial data are extracted
from an existing national neonatal EPR via the National
Neonatal Research Database (NNRD). In the UK, 430
clearly deﬁned data items (the Neonatal Data Set—http://
www.datadictionary.nhs.uk/data_dictionary/messages/clinical_
data_sets/data_sets/national_neonatal_data_set/national_
neonatal_data_set_-_episodic_and_daily_care_fr.asp?shownav=
0) are extracted from a national summary EPR system to
form the NNRD. Data protection complies with national
standards, appropriate regulatory approvals are held and all
parents are offered the opportunity to opt out of inclusion
of their baby’s data in the NNRD.
2. A short (2-page, 1000-word) parent information sheet (see
online supplementary data 1).
3. Explicit mention in the patient information sheet of the pos-
sibility of inclusion beneﬁt through participation: “Each of
the two options in the WHEAT study is currently used by
doctors in the UK because we do not know which one is
better. For babies not taking part in the WHEAT study, the
choice of whether or not to stop feeds is made according to
the preference of the local medical team. This non-evidence
based approach to neonatal care may involve more risk than
being in a study like WHEAT which involves a carefully
designed protocol and consistent monitoring”.
4. A consent process involving enrolment as the default unless
a parent opts out. This was described as follows: “Parents of
babies that meet the inclusion criteria will be approached by
members of the local clinical team after their baby is admit-
ted to the neonatal unit, usually in the ﬁrst 24 hours. Parents
will be provided with the parent information sheet that
explains the WHEAT trial and makes it clear that both arms
(withholding feeds and continuing feeds) represent current
clinical practice. The parent information sheet will make it
clear that opt-out consent is being requested. This means
that if they do not want their baby to take part in the
WHEAT trial, they can inform the local clinical team at any
point. If they do not do ‘opt out’ in this way then their baby
will be enrolled into WHEAT trial and will be randomised
to one of the two study arms. The local team will record in
the electronic health record that they have explained the
WHEAT trial and the ‘opt-out’ consent process to parents.”
The lay ‘Summary of the study’ and the ‘Summary of the
main [ethical] issues’ from the NHS REC form are shown in
boxes 1 and 2, respectively. The full Integrated Research
Application System (IRAS) form is provided in online
supplementary appendix 2.
Role of the HRA
We approached the HRA who agreed to assist with this study.
All REC chairs in England were contacted by the HRA and
invited to take part in a process that would involve an identical
study submitted to multiple RECs for the purpose of comparing
consistency, using the standard online submission process and
without identifying that the application was part of a multiple
submission.
Of the RECs that agreed to participate, the HRA identiﬁed
those that did not share a common administrative coordinator,
in order to reduce the likelihood of the study being identiﬁed as
part of a multiple submission. From these, we selected all RECs
for which it would be possible to attend meetings.
Box 1 Summary of study submitted to Research Ethics
Committees for the WithHolding Enteral feeds Around
packed red cell Transfusion (WHEAT) study
▸ The purpose of WHEAT is to compare two practices that are
widely used in neonatal units across the UK and around the
world to see if one reduces the risk of necrotising
enterocolitis (NEC) in babies born early (premature).
▸ NEC is a serious gut disease that affects about 1 in 20 very
premature babies (approximately 500 each year); about 1 in
3 of these babies will die of NEC and survivors often have
long-term health and developmental problems. In 2014,
prevention of NEC was ranked the third most important
research priority by parents and perinatal health
professionals.
▸ Premature babies receive frequent milk feeds (every 1 to
4 hours) and they often need blood transfusions because
they become anaemic (they do not have enough red blood
cells). Some doctors worry that feeding babies during a
blood transfusion may increase the risk of NEC. Others,
however, think that it is more dangerous to stop feeds.
Because of this, the way babies are cared for during blood
transfusions varies across the country; some babies have milk
feeds stopped before, during and after a transfusion (around
12 hours in total), while others have feeds continued.
▸ The purpose of WHEAT is to determine which approach is
best. We will do this by comparing babies who have feeds
stopped with those who have feeds continued during blood
transfusions. Whether feeds will be stopped or continued will
be decided by randomisation. Randomisation is done by
computer and ensures that each baby has an equal chance
of receiving either approach. WHEAT will compare standard
UK practices and involves nothing new. WHEAT will take
place in neonatal units all over the UK and will involve about
4500 babies.
▸ Professional opinion (National Health Service Blood and
Transplant, National Institute of Health Research Children’s
Clinical Research Network and most UK neonatal units)
supports the need for a trial like WHEAT.
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REC application
We prepared a REC IRAS application (see online supplementary
data 1), participant information sheet (see online supplementary
data 2), study protocol, researcher CV, valid sponsor letter and
insurance certiﬁcate (both from Imperial College London). The
application was booked centrally by the HRA to the selected
RECs; application documents were uploaded individually to
each REC by the researchers. REC coordinators who recognised
that an identical application had been submitted to multiple
committees were contacted by the HRA and taken into conﬁ-
dence so that REC members remained unaware of the identity
of the study.
Written responses to the RECs were standardised to ensure all
committees received the same information upon which to base
their opinion. Comments from individual REC and responses
from the researchers are provided in online supplementary
appendix 3. When challenged in relation to the four methodo-
logical approaches outlined above, the researchers responded by
defending the ethical validity of the proposed approach and did
not agree to its removal from the application. Where commit-
tees proposed other changes to the application, for example,
requiring the information" sheet to include details of local
Patient Advisory and Liaison Services, the researchers acceded
to the REC suggestions (described in more detail in online sup-
plementary data 3–14).
It was decided in advance that the REC decisions arising from
this study would not be used as formal REC approval for the
WHEAT trial. REC approval following a future application, to a
single REC, would be required before starting the WHEAT trial.
Study outcomes
The primary outcome was the number of RECs granting a ﬁnal
favourable opinion.
Secondary outcomes were:
▸ the number of RECs that raised queries regarding each of the
four approaches proposed to increase trial efﬁciency;
▸ process metrics: time to decision from submission of the
application, measured using the HRA methodology (in which
Box 2 Summary of main (ethical) issues submitted to Research Ethics Committees for the WithHolding Enteral feeds
Around packed red cell Transfusion (WHEAT) study
Opt-out consent
▸ In present day practice, consent to either continue or withhold feeds is not sought from parents. In WHEAT, parents will be offered
opportunity to opt-out of randomisation at any time and without having to give a reason. This reduces the risk of ‘injurious
misconception’ where parents reject trial participation because of the burden of decision-making and an exaggerated perception of
risk (Snowdon et al13). Full informed opt-out consent in the WHEAT trial will be a continuing process in which parents will be able to
review their decision over the course of their relationship with neonatal unit staff. Parent opt-out will be recorded in the baby’s
electronic health record.
▸ The opt-out approach is preferable because an opt-in approach is associated with a selection bias towards a healthier sample
( Junghans et al14) thus reducing the generalisability of study outcomes.
▸ The opt-out approach has been used previously in neonatal research, particularly in comparative effectiveness research such as
WHEAT where there is no research-related risk (as opposed to normal care-related risk).
Extracting trial data from routinely recorded clinical information
▸ The large sample size required to detect a clinically relevant effect on NEC would be expensive and challenging for standard trial
methodology. WHEAT is a registry trial, this means that all trial data will be obtained from a database that holds routinely recorded
clinical information, the National Neonatal Research Database (NNRD).
▸ All neonatal units in England and Wales contribute data to the NNRD, NNRD data are a National Health Service Information Standard
(ISB1595) and are extracted quarterly from real-time neonatal electronic health records. The NNRD is approved by the Caldicott
Guardians and Lead Clinicians of all contributing neonatal units, the National Research Ethics Service (10/H0803/151) and the
Conﬁdentiality Advisory Group of the Health Research Authority (805(f )/2010). The quality and completeness of data that will be
used in WHEAT have been validated against clinical paper notes and clinical trial Case Report Forms and high levels of agreement
have been shown. All parents of babies admitted to neonatal units are given an information sheet that explains the NNRD and its
uses (service evaluations, audit and approved research) and that if they wish they may choose to opt out of clinical data entered into
the electronic health records being held in the NNRD.
▸ Extracting trial data in this way will be more efﬁcient than conventional, duplicative, data collection and will increase value and
reduce waste in research (Chalmers I et al15).
▸ Use of the NNRD to support the trial has an additional fail-safe beneﬁt in that a baby’s data cannot be used for WHEAT unless there
is a positive entry in the baby’s electronic health record that the parent information sheet has been given and discussed with the
parents; this entry will be signed by the person registering this on the system.
Inclusion beneﬁt
▸ We have stated that there may be a beneﬁt of participating in clinical trials in the patient information sheet as follows: “Each of the
two options in the WHEAT study is currently used by doctors in the UK because we do not know which one is better. For babies not
taking part in the WHEAT study, the choice of whether or not to stop feeds is made according to the preference of the local medical
team. This non-evidence based approach to neonatal care may involve more risk than being in a study like WHEAT which involves a
carefully designed protocol and consistent monitoring”. Patients enrolled in randomised controlled trials, including those allocated to
the control arm, have better outcomes than comparable non-participants.
▸ This has been most recently demonstrated in a large neonatal trial (Carlo et al16), but the same beneﬁt has been detected in previous
neonatal (Schmidt et al17) and adult randomised trials (reviewed in Braunholtz et al18). We believe we have a duty to provide parents
with clear information about both the beneﬁts and the risks of research participation.
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the ‘clock’ stops while response is being prepared by the
researchers);
▸ amount of correspondence required to reach a ﬁnal REC
decision.
RESULTS
Eighty-eight UK RECs were asked by the HRA to take part in a
blinded, multiple submission exercise, in advance of the study.
Twenty-seven of 88 agreed to participate, no reasons were given
by the 61 RECs that chose not to participate. Six of the 27
RECs that agreed to participate were ﬂagged to receive paediat-
ric studies. Flagged RECs have speciﬁc expertise in reviewing a
particular type of study, in this case research involving children.
Six RECs meetings were attended by either MJH or CG in
person and they were available by telephone for the other six.
Four RECs telephoned MJH during their meeting.
MJH attended two meetings and both MJH and CG attended
four meetings. One REC asked the researchers to attend on two
occasions, with the second meeting in order to discuss applicant
responses to the decision letter issued by the RECs after the ﬁrst
meeting. The ﬁrst of these was attended by MJH and the
follow-up meeting was attended by both MJH and CG.
Four RECs coordinators recognised that an identical applica-
tion had been submitted to multiple committees and were
informed in conﬁdence of the study by the HRA.
One REC rejected the application outright without corres-
pondence with the researchers. Eleven RECs required written
responses from the researchers, of these nine provided a ﬁnal
favourable opinion and two rejected the application.
Eleven RECs asked for study documents to be amended
(median 2 documents; range 1–7). We provided written
responses comprising a median of 3 (range 1–13) pages and
941 words (range 164–5227). The median time from REC
meeting to ﬁnal decision was 14 working days (range 4–33).
REC comments on the four methodological aspects under
study
Details of the responses received relating to the proposed meth-
odological approaches are listed in table 1. No REC raised con-
cerns about the proposed point-of-care design using the EPR
data. One REC raised concerns about the short parent informa-
tion sheet. The committee initially requested “The participant
information sheet be re-written/re-formatted in line with [HRA]
guidance [for Clinical Trials of Investigational Medical
Products]”. In correspondence, we explained that HRA guid-
ance is not mandatory, does not ﬁt all research and that there is
evidence of a negative correlation between increasing length of
parent information sheet and participants’ understanding of the
research; we also demonstrated parent involvement in the
design of the information sheet. The short parent information
sheet was subsequently accepted by this REC.
All nine RECs that provided a favourable opinion raised con-
cerns about the mention of inclusion beneﬁt in the patient infor-
mation sheet. Following correspondence, the following
modiﬁed statement was considered acceptable and included in
the patient information sheet approved by all RECs:
Each of the two options in the WHEAT study is currently used
by doctors in the UK because we do not know which one is
better. For babies not taking part in the WHEAT study, the
choice of whether or not to stop feeds is made according to the
preference of the local medical team. Taking part in a research
study may confer non-speciﬁc beneﬁts.
Three RECs provided an unfavourable opinion because they
considered opt-out consent invalid. One committee accepted
that while there were justiﬁcations for an opt-out approach
these did not apply in relation to the WHEAT study (further
explanation not provided). Two other RECs indicated they con-
sidered this approach to consent to be more universally invalid.
One committee stated “as there is an opportunity to do so, [opt
in] consent should be sought from parents”, while another indi-
cated that “the ‘opt-out’ consent is not a concept that the
Committee recognises” deeming it to be ‘recruitment without
consent’. The remaining nine RECs provided a favourable
opinion for the WHEAT trial incorporating opt-out consent.
At the end of the study, we produced a feedback document
for RECs (see online supplementary data 15). This was deliv-
ered by the HRA to all the UK REC chairs and was accompan-
ied by a response from the HRA (see online supplementary
data 16).
DISCUSSION
We show that using EPR data in neonatal trials, short participant
information sheets, opt out consent and explicitly mentioning
inclusion beneﬁt are acceptable to a majority of the NHS RECs
included in this study. We identify inconsistency between RECs
in relation to whether ‘opt-out’ consent is ethically valid, with 3
of 12 RECs rejecting our application on these grounds. We also
show that the time taken by the UK NHS RECs to reach a ﬁnal
opinion was considerably less than the 60-day target set by the
HRA.
Strengths include blinding of RECs to the comparative nature
of the study, a priori deﬁned outcomes and the use of a genuine
clinical trial developed with extensive parent and multidisciplin-
ary input. To our knowledge, this is the ﬁrst blinded attempt to
examine the consistency of the UK REC decision-making since
the introduction in 2004 of a single UK-wide ethics application
process. Previously, the Research Ethics Service has used an
internal exercise known as shared ethical debate to examine con-
sistency. This approach is limited because the committee is
aware that it is part of an exercise to check consistency (and not
a ‘real’ application) and may therefore subject it to greater scru-
tiny than normal, or conversely conduct only cursory discus-
sions and reach a decision without the same degree of scrutiny
exercised for ‘real’ applications. To date, none of these internal
exercises has been published in the peer-reviewed literature.
Additionally, shared ethical debates do not involve discussion
with researchers, an important consideration as many issues
raised by applications are addressed in dialogue at committee
meetings or in correspondence. The key limitations of our study
are the uncertain generalisability of our ﬁndings to other patient
groups and beyond comparative effectiveness trials of commonly
used treatments.
Inconsistencies in REC decision-making are long-recognised.
The HRA has proposed a number of initiatives to make deci-
sions more consistent.19 These include greater engagement with
researchers and a formal mechanism for capturing and sharing
past decisions in relation to speciﬁc principles. We urge the
HRA to continue to monitor consistency, evaluate the effective-
ness of these initiatives and create a searchable repository of
decisions.
Stakeholders (including parents, parent representatives and
health professionals) were involved throughout the development
of WHEAT, and speciﬁcally considered opt-out consent to be
valid and appropriate. This is in keeping with national20 and
international21 guidance for comparative effectiveness research.
Although most RECs considered and incorporated this
F4 Gale C, et al. Arch Dis Child Fetal Neonatal Ed 2016;0:F1–F8. doi:10.1136/archdischild-2016-310935
Original article
group.bmj.com on September 20, 2016 - Published by http://fn.bmj.com/Downloaded from 
Table 1 Summary of responses received from individual Research Ethics Committees
Research
Ethics
Committee
Paediatric
flagged
Attended
in person
Discussed
on phone Decision Opt-out consent Streamlined PIS Inclusion benefit
Electronic
healthcare
data
1 Yes No No Accept, with
modifications
No concerns raised No concerns raised Initial judgement:
“In the section ‘Are there any benefits for my
baby’ please delete the third sentence starting
‘This non-evidence based approach …’”
Subsequently accepted modified wording
No concerns
raised
2 Yes Yes No Accept, with
modifications
No concerns raised No concerns raised Initial judgement:
“Please amend the sentence ‘This non-evidence
based approach to neonatal care may involve
more risk than being in a study like WHEAT which
involves a carefully designed
protocol and consistent monitoring’ under the
heading ‘Are there any benefits for my baby?’ as
it could be considered coercive”.
Subsequently accepted modified wording
No concerns
raised
3 Yes Yes No Accept, with
modifications
Required the following to be added to the protocol
“The person conducting the consent discussion
should provide a clear, well written documentation
in patient paper notes to document the entire
consent process and clarifying the option taken
(opt in/ opt out) by the parents”
No concerns raised No concerns raised No concerns
raised
4 No Yes No Reject—after
further
discussion
Judgement:
“The REC remained unhappy with an opt-out
process. They discussed the possibility of providing
a consent form for parents to evidence they had
opted out, but on reflection agreed if this was
possible it should be possible to provide an opt-in
consent form and change the process accordingly.
… The Committee agreed it was essential parents
were asked to sign an agreement (either opt-out
or opt-in) to ensure they personally understood
exactly what they were consenting their children
to.
The Committee felt the concept of an opt-out
study would indicate to parents there was no risk
involved in the study, which would influence their
decision to participate. … They acknowledged
there were justifications for opt-out studies, but
did not believe they applied in this case.
The REC require the consent process to be
changed to an ‘opt in’ system, and a consent form
provided for review. This should be provided to
parents alongside the information sheet, and the
protocol updated to reflect this”
Initial judgement:
“The participant information sheet
should be rewritten/reformatted in
line with NRES guidance, to ensure
all pertinent areas are covered”.
Having demonstrated that there was
nothing absent in the PIS that was
suggested by NRES guidelines,
abbreviated PIS was accepted
Initial judgement:
“The sentence within the ‘Are there any benefits
for my baby?’ section stating ‘This non evidence
based approach to neonatal care may involve
more risk than being in a study like WHEAT which
involves a carefully designed protocol and
consistent monitoring’ must be removed. Note:
Giving this kind of information to potential
participants by inclusion in a general information
leaflet about research is considered to be
reasonable, though the particular wording should
be reviewed within the institution guidelines”
Subsequently accepted modified wording
No concerns
raised
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Table 1 Continued
Research
Ethics
Committee
Paediatric
flagged
Attended
in person
Discussed
on phone Decision Opt-out consent Streamlined PIS Inclusion benefit
Electronic
healthcare
data
5 No No Yes Accept, with
modifications
Initial judgement:
“The Committee requests further justification for
the proposed use of opt-out consent”. AND “The
Committee requests clarification of the process
should a parent decide to opt out of the study,
and confirmation that no undue pressure or
influence would be placed on them, even if
unintentionally (for example, by asking them to
sign a form to opt out, when this is not required
at the time of initial consent)”.
Subsequently accepted opt-out consent with
condition we provided parents with a card to
prove their participation and explaining the
opt-out process
No concerns raised Initial judgement:
“Please remove the final sentence of the section
‘Are there any benefits for my baby?’. It is
disingenuous to include this statement about
“non-evidence based approach” in the PIS since
evidence based care simply means care that is
compatible with the current state of evidence”.
Subsequently accepted modified wording
No concerns
raised
6 Yes No Yes Accept, with
modifications
No concerns raised No concerns raised Initial judgement:
“Removal of the following sentence in the
Participant Information Sheet: “This non-evidence
based approach to neonatal care may involve
more risk than being in a study like WHEAT which
involves a carefully designed protocol and
consistent monitoring”.
Subsequently accepted modified wording
No concerns
raised
7 Yes Yes No Reject—after
further
discussion
Initial judgement:
“The Committee decided that, as there is an
opportunity to do so, consent should be sought
from parents. The design should be changed from
opt out to opt in. Therefore, please submit a
consent form for completion by parents”
No concerns raised Initial judgement:
“Please remove the last sentence from the section
headed Are there any benefits for my baby? In the
Participant Information Sheet”.
Subsequently accepted modified wording
No concerns
raised
8 No No Yes Reject “The Committee did not accept that it was
appropriate for patients to be entered into this
study without prior consent from parents. The
‘opt-out’ consent is not a concept that the
Committee recognises; it is recruitment without
consent. This raised many ethical issues which
have not been addressed. The Committee also
considered that written evidence of consent would
protect researchers from future action by parents
or authorities in the event of adverse outcomes,
which are not rare in this very vulnerable patient
population”
No concerns raised “The Committee thought the Parent Information
Sheet was coercive in places, stating it was better
to be in the study than not”
No concerns
raised
9 No Yes No Accept, with
modifications
No concerns raised No concerns raised Initial judgement:
“Are there any Benefits…? Section—delete the
last sentence”.
Subsequently accepted modified wording
No concerns
raised
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stakeholder involvement when reaching their decision, it is con-
cerning that three RECs appeared to give less weight to the
views of stakeholders, rejecting our application on the ground
of opt-out consent. While opt-out consent is unlikely to be
appropriate for studies where there is risk from exposure to
non-routine or novel experimental agents or practices, it may
actually be preferable for comparative effectiveness research as it
results in higher recruitment and a less biased sample.22 In
determining the ethically appropriate limits for opt-out consent,
it is essential to involve patients, public and frontline health pro-
fessionals, in addition to academics and ethicists. This may be
better served through a case-by-case approach, rather than more
rigid ‘top-down’ guidance.
Inclusion beneﬁt is well described in the context of neonatal
randomised controlled trials,4 23 most recently in the SUPPORT
trial24 where infants in both treatment groups had lower rates of
death than similar infants not enrolled in the trial. The
Declaration of Helsinki states that “each potential subject must be
adequately informed of the… anticipated beneﬁts and potential
risks of the study”.25 We hold that informing research participants
of potential beneﬁts is as essential as discussing the risk of harm.
We accept that the evidence for inclusion beneﬁt is controversial,
in particular in relation to point-of-care comparative effectiveness
trials that aim for high participation rates. We suggest that, where
possible, clinical trials should endeavour to collect aggregate anon-
ymised primary outcome data from comparable patient groups not
enrolled in the trial to inform future discussion about the potential
harms and beneﬁts of research participation.
Using routinely available EPR data in point-of-care trials or
randomised registry trials has substantial potential to increase
efﬁciency.26 Such trials are ongoing in the UK (http://www.nets.
nihr.ac.uk/projects/hta/1449127) and internationally.27 It is
reassuring that no REC raised concerns about this approach
given the potential to reduce research waste across many
medical disciplines.
In many countries, researchers are required to obtain inde-
pendent ethics review at each participating site for a multicentre
study. This adds considerable administrative burden and also
increases the likelihood of inconsistency in research ethics
review28–30 that is largely hidden in the UK by the single
approval system. Our study in conjunction with international
evidence indicates that inconsistency in decision-making is com-
monplace across countries and healthcare systems; this serves
neither patients nor researchers well and risks breakdowns in
trust. This highlights the importance of sound policies to
improve REC consistency.
Our study indicates that where an REC raises concerns that a
researcher feels are unjustiﬁed, a clear written defence explain-
ing the ethical basis, citing supporting precedent and demon-
strating meaningful patient-public involvement is warranted. If
this still results in an unfavourable opinion, we suggest resubmis-
sion to another REC including detailed justiﬁcation of the
approach adopted, in accordance with the HRA guidance.
Well-designed and appropriately powered clinical trials are
essential to resolve uncertainty. Such trials require effective
recruitment and data collection. It is reassuring that the major-
ity of the UK RECs consider all four proposed approaches,
namely point-of-care trial designs using the EPR data, short
patient information sheets, recognition of the possibility of
inclusion beneﬁt and opt-out consent for comparative effect-
iveness research to be valid. We suggest that these approaches
should be applied more widely to facilitate large, simple trials,
reduce research waste and speed reductions in uncertainties in
care.
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